Pearl matrixBone Graft Here's an article about PearlMatrix FDA approval, incorporating the provided data:
The PearlMatrix P-15 Peptide Enhanced Bone Graft has achieved significant milestone with its FDA approval, marking a pivotal moment in the treatment of degenerative disc disease in the lumbar spine.2025年7月9日—PearlMatrix is the first and only bone graft approved through the PMA pathwaythat is specifically proven to FDA premarket approval (PMA). This innovative drug-device combination product, developed by Cerapedics, is recognized as the first and only bone growth accelerator proven to accelerate lumbar fusion.2026年1月13日—Cerapedics was granted FDA approvalfor an expansion to the indications for use and labeling for PearlMatrix P-15 Peptide Enhanced Bone Graft ... The initial FDA premarket approval (PMA) of PearlMatrix was granted in June 2025, with the Date of FDA Notice of Approval officially recorded as June 18, 2025. This groundbreaking development offers a new therapeutic option for adult patients suffering from degenerative disc disease, specifically indicated for use at one level in the lumbar spine (L2-S1) with up to Grade I spondylolisthesis.
PearlMatrix P-15 is built upon Cerapedics' proprietary P-15 peptide technology. This technology is designed to mimic natural bone-building processes, encouraging osteogenic cell binding. Unlike traditional bone grafts, the P-15 peptide acts as a cellular attractant and activator, significantly enhancing the body's natural ability to fuse bone segments. This mechanism is crucial for achieving solid fusion, which is the ultimate goal in surgical treatments for conditions like degenerative disc disease.Cerapedics gets FDA approval for PearlMatrix Bone Graft The Class III FDA approved bone graft has demonstrated its efficacy in rigorous clinical trials, providing substantial data supporting its role in spinal fusion procedures.
The journey to widespread adoption for PearlMatrix P-15 has been marked by key regulatory achievementsPearlMatrix P-15 Peptide Enhanced Bone Graftis the first and only bone growth accelerator proven to accelerate lumbar fusion.. Following its initial FDA approval in June 2025, Cerapedics has continued to advance the product's utility.作者：JS Harrop·2025·被引用次数：1—Both ABM/P-15 and P-15L utilize P-15 peptide technology, butonly P-15L is FDA approvedfor use during transforaminal lumbar interbody fusion (TLIF) procedures. Notably, on January 13, 2026, Cerapedics was granted FDA approval for an expansion to the indications for use and labeling for PearlMatrix P-15 Peptide Enhanced Bone Graft. This expansion allows for broader application across major lumbar spinal procedures, further solidifying its position in the market. The PearlMatrix P-15 Peptide Enhanced Bone Graft is now approved for use in various lumbar fusion procedures, including transforaminal lumbar interbody fusion (TLIF), where it plays a critical role in accelerating the fusion processPearlMatrixTMP-15 Peptide Enhanced Bone Graftis the first and only bone growth accelerator shown to accelerate lumbar fusion in both the overall and ....
The clinical significance of PearlMatrix P-15 lies in its ability to substantially increase lumbar fusion speed.Cerapedics Treats First U.S. Patient with PearlMatrix™ ... Studies indicate that the PearlMatrix bone graft received US FDA pre-market approval in June 2025 and has since shown promise in improving patient outcomes by reducing the time to fusion. This acceleration can lead to faster recovery times and a quicker return to daily activities for patients. The product's designation as a Breakthrough Device by the FDA further underscores its potential to revolutionize spinal surgeryPearlMatrix™ P-15 Peptide Enhanced Bone Graft, ...Date of FDA Notice of Approval: June 18, 2025. Breakthrough Device: Granted breakthrough device status on .... The Class III drug-device combination product designation highlights its complex nature and the rigorous standards it has met for safety and effectivenessP-15 Peptide Enhanced Bone Graft Improves Time to Fusion ....
Cerapedics' success with PearlMatrix P-15 underscores the importance of robust clinical data and navigating the FDA's regulatory pathways effectively.Cerapedics Announces First U.S. Patient Treated with ... The product's approval through the Premarket Approval (PMA) pathway signifies a high level of scrutiny and validation. While the PearlMatrix P-15 Peptide Enhanced Bone Graft has received widespread approval, it's important to note that specific product variations, such as P-15L, are FDA approved for particular procedures like TLIF2025年8月14日—In June2025, the company securedFDApremarketapprovalfor itsPearlMatrix™P-15 Peptide Enhanced Bone Graft— and now they've marked .... The company's commitment to innovation is evident in its pursuit of expanded indications, ensuring that the benefits of P-15 peptide technology are accessible to a wider patient population. The FDA approval process is stringent, and obtaining such clearance for a Class III FDA approved bone graft is a testament to the product's safety and efficacy.
The FDA approval of the PearlMatrix P-15 Peptide Enhanced Bone Graft represents a significant advancement in orthopedic and spinal surgeryPearlMatrix P-15 Peptide Enhanced Bone Graft - MEARIS - CMS. As the first and only bone growth accelerator proven to accelerate lumbar fusion, it offers a compelling solution for patients with degenerative disc disease. With expanded indications and a strong foundation in P-15 peptide technology, PearlMatrix is poised to become a cornerstone treatment, enhancing fusion rates and improving patient recovery timelines in the years to come...PearlMatrix™P-15 Peptide Enhanced Bone Graft( ... Date Received, 09/08/2025. Decision Date, 12/11/2025. Product Code, NOX24. Advisory Committee .... The ongoing development and regulatory milestones achieved by Cerapedics highlight a commitment to innovation and patient well-being in the field of bone regeneration.FDA Approves First Bone Growth Accelerator for Spinal ...
Join the newsletter to receive news, updates, new products and freebies in your inbox.